Kimberley J Smith1, Suzanne Norris2, Susan McKiernan2, Barbara Hynes2, Anne M O'Dwyer3, Shane M O'Mara4. 1. Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland ; Douglas Mental Health University Institute, McGill University, Montreal, Canada. 2. Hepatology Centre, St. James's Hospital, Dublin, Ireland. 3. Psychological Medicine Service, St James's Hospital, Dublin, Ireland. 4. Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland.
Abstract
OBJECTIVE: The most investigated adverse event associated with interferon-alpha (IFN-α) treatment is depressed mood, with many studies finding a significant increase in depression scale scores from baseline to treatment. This paper is concerned with exploring discrete categories of depressive symptoms (somatic, behavioral, negative cognitions and depressed mood) in order to explore the behavioral syndrome associated with IFN-α. METHODS: Thirty-five Hepatitis C patients due to commence IFN-α treatment were assessed using the Structured Clinical Interview (SCID), and the 24-item Hamilton Depression Inventory (HAM-D) at 0 and 8 weeks. RESULTS: Somatic symptoms comprised the significant majority of scores across all weeks for patients taking IFN-α. Patients who developed a depression had significantly more somatic and mood symptoms at Week 8 than those patients who did not develop a depression. CONCLUSIONS: These exploratory results indicate that the increase in raw depression scores is due to an increase in somatic and mood symptoms, rather than negative cognitions. However, this increase does not correspond to a proportional increase in a particular subscale. These results also indicate that development of an IFN-α-induced depression is due to mood symptoms rather than negative cognitions.
OBJECTIVE: The most investigated adverse event associated with interferon-alpha (IFN-α) treatment is depressed mood, with many studies finding a significant increase in depression scale scores from baseline to treatment. This paper is concerned with exploring discrete categories of depressive symptoms (somatic, behavioral, negative cognitions and depressed mood) in order to explore the behavioral syndrome associated with IFN-α. METHODS: Thirty-five Hepatitis C patients due to commence IFN-α treatment were assessed using the Structured Clinical Interview (SCID), and the 24-item Hamilton Depression Inventory (HAM-D) at 0 and 8 weeks. RESULTS: Somatic symptoms comprised the significant majority of scores across all weeks for patients taking IFN-α. Patients who developed a depression had significantly more somatic and mood symptoms at Week 8 than those patients who did not develop a depression. CONCLUSIONS: These exploratory results indicate that the increase in raw depression scores is due to an increase in somatic and mood symptoms, rather than negative cognitions. However, this increase does not correspond to a proportional increase in a particular subscale. These results also indicate that development of an IFN-α-induced depression is due to mood symptoms rather than negative cognitions.
Entities:
Keywords:
HAM-D, Hamilton depression inventory; HCV, Hepatitis C virus; Hepatitis C; IFN-α, Interferon-alpha; MDD, Major depressive disorder; PAEs, Psychiatric adverse events; PEG, pegylated; SCID, Structured clinical interview; SCID, statistical manual for psychiatric disorders; depression; interferon-alpha; sickness behavior
Authors: Robert Dantzer; Jason C O'Connor; Gregory G Freund; Rodney W Johnson; Keith W Kelley Journal: Nat Rev Neurosci Date: 2008-01 Impact factor: 34.870
Authors: Lucile Capuron; Fiona B Fornwalt; Bettina T Knight; Philip D Harvey; Philip T Ninan; Andrew H Miller Journal: J Affect Disord Date: 2009-03-06 Impact factor: 4.839
Authors: Martin Schaefer; Folkhard Schmidt; Christian Folwaczny; Reinhard Lorenz; Gaby Martin; Norbert Schindlbeck; Walter Heldwein; Michael Soyka; Heinz Grunze; August Koenig; Klaus Loeschke Journal: Hepatology Date: 2003-02 Impact factor: 17.425
Authors: P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell Journal: Mol Psychiatry Date: 2002 Impact factor: 15.992